Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Thymic neuroendocrine carcinoma is a type of thymic epithelial neoplasm displaying evidence of neuroendocrine differentiation.
Biomarker and diagnostic research for thymic neuroendocrine carcinoma has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
2 clinical trials registered. Interventions under study include other interventions and biologic therapy. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
31 publications have been identified in PubMed for thymic neuroendocrine carcinoma. Research spans Review / Meta-Analysis (39%), Case Report / Case Series (23%), and Clinical Trial Publication (13%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 12 |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 4:32 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Patient case studies | 7 | 23% |
Clinical study results | 4 | 13% |
Disease patterns and progression | 3 | 10% |
Testing and diagnosis research | 2 | 6% |
Laboratory research | 2 | 6% |
Other research | 1 | 3% |
Nabel CS (2026). [PMID: 41847153](https://pubmed.ncbi.nlm.nih.gov/41847153/). *JTO Clin Res Rep*. [Epidemiology / Natural History]
Romanucci M (2026). [PMID: 42070672](https://pubmed.ncbi.nlm.nih.gov/42070672/). *J Equine Vet Sci*. [Case Report / Case Series]
Østergaard T (2026). [PMID: 42165211](https://pubmed.ncbi.nlm.nih.gov/42165211/). *Acta Oncol*. [Epidemiology / Natural History]
Oliveira K (2026). [PMID: 42199998](https://pubmed.ncbi.nlm.nih.gov/42199998/). *Case Rep Pathol*. [Case Report / Case Series]
Ardeshir-Larinani F (2026). [PMID: 41961041](https://pubmed.ncbi.nlm.nih.gov/41961041/). *J Thorac Oncol*. [Review / Meta-Analysis]
Madrid OA (2026). [PMID: 32809638](https://pubmed.ncbi.nlm.nih.gov/32809638/). *Unknown Journal*. [Review / Meta-Analysis]
Tavazzi G (2026). [PMID: 42095362](https://pubmed.ncbi.nlm.nih.gov/42095362/). *Ultrasound J*. [Other]
Maluf H (2025). [PMID: 38199878](https://pubmed.ncbi.nlm.nih.gov/38199878/). *Semin Diagn Pathol*. [Review / Meta-Analysis]
Shan BW (2025). [PMID: 41480169](https://pubmed.ncbi.nlm.nih.gov/41480169/). *World J Clin Oncol*. [Case Report / Case Series]
Suster DI (2025). [PMID: 38884541](https://pubmed.ncbi.nlm.nih.gov/38884541/). *Arch Pathol Lab Med*. [Diagnostic / Biomarker]
AI-curated news mentioning thymic neuroendocrine carcinoma
Updated Apr 28, 2026
A study explores the use of peptide receptor radionuclide therapy (PRRT) and osilodrostat for treating ectopic Cushing syndrome caused by thymic neuroendocrine neoplasms. This research contributes to understanding treatment options for this rare condition.